Trane Technologies plc (TT)
After hours:
| Previous close | 325.00 |
| Open | 325.77 |
| Bid | 324.20 x 900 |
| Ask | 325.48 x 800 |
| Day's range | 319.16 - 327.65 |
| 52-week range | 171.63 - 338.09 |
| Volume | |
| Avg. volume | 939,447 |
| Market cap | 74.121B |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | 34.62 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.36 (1.03%) |
| Ex-dividend date | 07 Jun 2024 |
| 1y target est | N/A |
- PR Newswire
Trane Technologies Accelerates Growth through Leading Sustainability Performance
Trane Technologies (NYSE: TT), a global climate innovator, is accelerating growth and delivering continued, industry-leading financial performance while advancing the company's bold 2030 Sustainability Commitments.
- Business Wire
Range Energy and Thermo King Collaborate to Advance the Commercial Adoption of Electric Refrigerated Trailers in the Americas
MOUNTAIN VIEW, Calif. & MINNEAPOLIS, May 09, 2024--Range Energy (Range), the hardware company bringing powered trailers to the commercial trucking market, and Thermo King, a leader in sustainable transport temperature control solutions and strategic brand of Trane Technologies (NYSE: TT), today announced a strategic collaboration to advance the commercialization of electric refrigerated trailers in the Americas.
- PR Newswire
Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma
Acepodia (6976:TT), a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms to address gaps in cancer care, today announced preliminary data from its Phase 1 dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin's lymphoma (NHL).
